Sharma E, Dahal S, Sharma P, et al. The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018;10:363–640. https://doi.org/10.14740/jocmr3503w.

Article  Google Scholar 

Kerkhofs TMA, Verhoeven RHA, van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:P2579-2586. https://doi.org/10.1016/j.ejca.2013.02.034.

Article  Google Scholar 

Jing Y, Hu J, Luo R, et al. Prevalence and characteristics of adrenal tumors in an unselected screening population. Ann Int Med. 2022;175:1383–91. https://doi.org/10.7326/M22-1619.

Article  PubMed  Google Scholar 

Libé R, Huillard O. Adrenocortical carcinoma: diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun. 2023;37:100759. https://doi.org/10.1016/j.ctarc.2023.100759.

Article  PubMed  Google Scholar 

Sada A, Foster TR, Al-Ward R, et al. The effect of hormonal secretion on survival in adrenocortical carcinoma: a multi-center study. Surgery. 2024;175:80–9. https://doi.org/10.1016/j.surg.2023.04.070.

Article  PubMed  Google Scholar 

Nastos C, Papaconstantinou D, Paspala A, et al. The impact of adrenocortical carcinoma hormone secreting status as a predictor of poor survival: a systematic review. Langenbecks Arch Surg. 2024;409:316. https://doi.org/10.1007/s00423-024-03507-5.

Article  PubMed  Google Scholar 

Spartalis E, Drikos I, Ioannidis A, et al. Metastatic carcinomas of the adrenal glands: from diagnosis to treatment. Anticancer Res. 2019;39:2699–710. https://doi.org/10.21873/anticanres.13395.

Article  CAS  PubMed  Google Scholar 

Frey S, Caillard C, Toulgoat F, Drui D, Hamy A, Mirallié E. Non-adrenal tumors of the adrenal area: what are the pitfalls? J Visceral Surg. 2020;157:217–30. https://doi.org/10.1016/j.jviscsurg.2020.02.004.

Article  CAS  Google Scholar 

Younes N, Bordeau I, Olney H, et al. Adrenocortical cancer recurrence following initial transcutaneous biopsy: a rare demonstration of needle tract seeding. Endoc Oncol. 2021;1:K7–12. https://doi.org/10.1530/EO-21-0031.

Article  Google Scholar 

Hue JJ, Bingmer K, Zhao H, et al. Reassessing the impact of tumor size on operative approach in adrenocortical carcinoma. J Surg Oncol. 2021;123:1238–45. https://doi.org/10.1002/jso.26418.

Article  PubMed  Google Scholar 

Nakanishi H, Miangul S, Wang R, et al. Open versus laparoscopic surgery in the management of adrenocortical carcinoma: a systematic review and meta-analysis. Endocrine Tumors. 2023;30:994–1005. https://doi.org/10.1245/s10434-022-12711-w.

Article  Google Scholar 

Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: european society of endocrinology clinical practice guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175:G1–34. https://doi.org/10.1530/EJE-16-0467.

Article  CAS  PubMed  Google Scholar 

Beuschlein F, Weigel J, Saeger W, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100:841–9. https://doi.org/10.1210/jc.2014-3182.

Article  CAS  PubMed  Google Scholar 

Del Rivero J, Else T, Hallanger-Johnson J, et al. A review of mitotane in the management of adrenocortical cancer. Oncologist. 2024;29:747–60. https://doi.org/10.1093/oncolo/oyae084.

Article  PubMed  PubMed Central  Google Scholar 

Bianchini M, Puliani G, Chiefari A, Mormando M, Lauretta R, Appetecchia M. Metabolic and endocrine toxicities of mitotane: a systematic review. Cancers. 2021;13:5001. https://doi.org/10.3390/cancers13195001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corso CR, Acco A, Bach C, Bonatto SJB, de Figueiredo RC, de Souza LM. Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br J Clin Pharmacol. 2021;87:2698–710. https://doi.org/10.1111/bcp.14721.

Article  PubMed  Google Scholar 

Tang Y, Li Z, Zou Z, Liang J, Lu Y, Zhu Y. Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis. BioMed Res Int. 2018. https://doi.org/10.1155/2018/9362108.

Article  PubMed  PubMed Central  Google Scholar 

Terzolo M, Fassnacht M, Perotti P, et al. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. Lancet Diabetes Endocrinol. 2023;11:720–30. https://doi.org/10.1016/S2213-8587(23)00193-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basile V, Puglisi S, Altieri B, et al. What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question. J Personaliz Med. 2021;11:269. https://doi.org/10.3390/jpm11040269.

Article  Google Scholar 

Wu L, Chen J, Su T, et al. Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma. Front Endocrinol. 2024;14:1308231. https://doi.org/10.3389/fendo.2023.1308231.

Article  Google Scholar 

Zhu J, Zheng Z, Shen J, et al. Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. Radiat Oncol. 2020;15:118. https://doi.org/10.1186/s13014-020-01533-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gharzai L, Green MD, Griffith KA, et al. Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma. J Clin Endocrinol Metab. 2019;104:3743–50. https://doi.org/10.1210/jc.2019-00029.

Article  PubMed  PubMed Central  Google Scholar 

Srougi V, Junior JB, Tanno FY, et al. Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best? Int Braz J Urol. 2017. https://doi.org/10.1590/S1677-5538.IBJU.2017.0095.

Article  PubMed  PubMed Central  Google Scholar 

Sabolch A, Else T, Griffith KA, et al. Adjuvant radiation therapy improves local control after surgical resection in localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2015;92:252–9. https://doi.org/10.1016/j.ijrobp.2015.01.007.

Article  PubMed  Google Scholar 

Habra MA, Ejaz S, Das P, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192–7. https://doi.org/10.1210/jc.2012-2367.

Article  CAS  PubMed  Google Scholar 

Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1477–84. https://doi.org/10.1016/j.ijrobp.2010.04.030.

Article  PubMed  Google Scholar 

Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501–4. https://doi.org/10.1210/jc.2006-1007.

Article  CAS  PubMed  Google Scholar 

Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;99:455–61. https://doi.org/10.1210/jc.2013-2856.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdel-Rahman O. Impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinoma—a real-world, population-based study. Strahlenther Onkol. 2022;198:73–9. https://doi.org/10.1007/s00066-021-01838-6.

Article  PubMed  Google Scholar 

Wu K, Liu X, Liu Z, Lu Y, Wang X, Li X. Benefit of postoperative radiotherapy for patients with nonmetastatic adrenocortical carcinoma: a population-based analysis. J Natl Compr Canc Netw. 2021;19:1425–32. https://doi.org/10.6004/jnccn.2021.7035.

Article  PubMed  Google Scholar 

Ginsburg KB, Chandra AA, Schober JP, et al. Identi